ABF Pharmaceutical Services GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Vienna Austria (2004)

Organization Overview

First Clinical Trial
2015
NCT02502903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ABF Pharmaceutical Services GmbH

Active Ingredients

Drugs in Phase 2 Trials (4)

emapalumab-lzsg (gamifant) (1 trial)

mv-chik (1 trial)

priorix (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

tnt009 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Hemolytic (Phase 1)

Anemia, Hemolytic, Autoimmune (Phase 1)

Chikungunya Fever (Phase 2)

Kidney Failure, Chronic (Phase 1)

Pemphigoid, Bullous (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5